Ionis Pharmaceuticals Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IONS?
Source: seekingalpha
- Sales Estimate Increase: Ionis Pharmaceuticals has raised its annual peak sales estimate for Olezarsen from over $2 billion to over $3 billion, reflecting continued demand growth for severe hypertriglyceridemia, with the FDA accepting priority review and a PDUFA date set for June 30.
- Significant Revenue Growth: Total revenue for Q1 2026 reached $246 million, an 87% increase year-over-year, including approximately $95 million in milestone payments from multiple partnerships, indicating strong performance in both product sales and collaboration revenue.
- Improved Financial Guidance: Ionis expects total revenue in the range of $875 million to $900 million for 2026, with a slight increase in commercial revenue share, while projecting a non-GAAP operating loss between $425 million and $475 million, reflecting confidence in future financial performance.
- Product Sales Outlook: The company anticipates full-year sales for TRYNGOLZA and DAWNZERA to be between $100 million and $110 million and $110 million and $120 million, respectively, although a significant decline in second-quarter TRYNGOLZA revenue is expected due to the price reset effective April 1, with a gradual recovery anticipated post-June 30 approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 71.780
Low
65.00
Averages
92.67
High
110.00
Current: 71.780
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ionis Pharmaceuticals Q1 2026 Earnings Call Highlights
- Sales Estimate Increase: Ionis Pharmaceuticals has raised its annual peak sales estimate for Olezarsen from over $2 billion to over $3 billion, reflecting continued demand growth for severe hypertriglyceridemia, with the FDA accepting priority review and a PDUFA date set for June 30.
- Significant Revenue Growth: Total revenue for Q1 2026 reached $246 million, an 87% increase year-over-year, including approximately $95 million in milestone payments from multiple partnerships, indicating strong performance in both product sales and collaboration revenue.
- Improved Financial Guidance: Ionis expects total revenue in the range of $875 million to $900 million for 2026, with a slight increase in commercial revenue share, while projecting a non-GAAP operating loss between $425 million and $475 million, reflecting confidence in future financial performance.
- Product Sales Outlook: The company anticipates full-year sales for TRYNGOLZA and DAWNZERA to be between $100 million and $110 million and $110 million and $120 million, respectively, although a significant decline in second-quarter TRYNGOLZA revenue is expected due to the price reset effective April 1, with a gradual recovery anticipated post-June 30 approval.
See More
Ionis Pharmaceuticals Q1 Earnings Beat Expectations with 86.4% Revenue Growth
- Strong Earnings Report: Ionis Pharmaceuticals reported a Q1 GAAP EPS of -$0.56, beating expectations by $0.35, with revenue reaching $246 million, reflecting an impressive 86.4% year-over-year growth that boosts investor confidence.
- Cash Flow Status: As of March 31, 2026, Ionis had $1.9 billion in cash and short-term investments, a decrease of $633 million from year-end 2025, primarily due to the maturity of 0% convertible notes, indicating challenges in cash management.
- Sales Guidance Upgrade: The company raised its peak net sales guidance for olezarsen from over $2 billion to over $3 billion, driven by increased confidence in the sHTG market opportunity, signaling optimism for future growth.
- Improved 2026 Financial Guidance: Ionis revised its 2026 total revenue guidance from $800-825 million to $875-900 million, while reducing operating loss expectations from $500-550 million to $425-475 million, reflecting strong revenue performance and ongoing commercial success.
See More
Ionis (IONS) Q1 2026 Earnings Call Transcript
See More
Ionis Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Announcement: Ionis Pharmaceuticals is set to release its Q1 2023 earnings on April 29 before the market opens, with consensus EPS estimated at -$0.78 and revenue projected at $196.01 million, reflecting a 48.5% year-over-year increase.
- Earnings Estimate Adjustments: Over the last three months, EPS estimates have seen no upward revisions and three downward adjustments, while revenue estimates have experienced one upward revision and six downward changes, indicating market caution regarding Ionis's future performance.
- Product Review Progress: Ionis's zilganersen has received Priority Review for Alexander disease, which could support future revenue growth, although the overall market environment remains uncertain.
- Market Environment Impact: Amid disruptions in the Middle East, Ionis Pharmaceuticals and other healthcare stocks are viewed as oversold, potentially presenting buying opportunities for investors looking for value in the sector.
See More
GSK Receives FDA Priority Review for Hepatitis B Therapy
- FDA Priority Review: GSK announced that its hepatitis B therapy, bepirovirsen, has received priority review from the FDA, with a target action date of October 26, 2026, potentially offering a new treatment option for approximately 1.7 million patients in the U.S., significantly enhancing GSK's competitive position in the liver disease market.
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy designation for the New Drug Application, indicating its potential for significant clinical benefits in treating chronic hepatitis B, which further bolsters GSK's R&D reputation and market confidence.
- Successful Clinical Trials: The NDA is supported by data from the Phase 3 B-Well 1 and B-Well 2 trials, which met primary endpoints and demonstrated statistically significant and clinically meaningful functional cure rates, indicating GSK's innovative potential in chronic hepatitis B treatment.
- Global Regulatory Reviews: In addition to the U.S., bepirovirsen is undergoing regulatory reviews in Europe, Japan, and China, and if approved, it will further expand GSK's international market presence and strengthen its global business strategy.
See More
FDA Accepts Priority Review for Bepirovirsen by GSK and Ionis
- FDA Priority Review: The FDA has accepted GSK's New Drug Application for Bepirovirsen, developed in partnership with Ionis, for priority review, marking a significant advancement in chronic hepatitis B treatment, with a decision expected by October 26, 2026.
- Breakthrough Therapy Designation: Bepirovirsen has received Breakthrough Therapy designation from the FDA, indicating its potential in treating chronic hepatitis B, which may provide new treatment options for patients and enhance market competitiveness.
- Clinical Trial Support: The regulatory submission is supported by positive results from the global B-Well 1 and B-Well 2 trials, which demonstrated statistically significant functional cure rates, thereby bolstering its credibility for clinical use.
- International Regulatory Review: Bepirovirsen is also under review by the European Medicines Agency, the China National Medical Products Administration, and Japan's Ministry of Health, Labour and Welfare, highlighting its global market potential and broad impact on chronic hepatitis B patients.
See More
Ionis Pharmaceuticals Q1 2026 Earnings Call Highlights
- Sales Estimate Increase: Ionis Pharmaceuticals has raised its annual peak sales estimate for Olezarsen from over $2 billion to over $3 billion, reflecting continued demand growth for severe hypertriglyceridemia, with the FDA accepting priority review and a PDUFA date set for June 30.
- Significant Revenue Growth: Total revenue for Q1 2026 reached $246 million, an 87% increase year-over-year, including approximately $95 million in milestone payments from multiple partnerships, indicating strong performance in both product sales and collaboration revenue.
- Improved Financial Guidance: Ionis expects total revenue in the range of $875 million to $900 million for 2026, with a slight increase in commercial revenue share, while projecting a non-GAAP operating loss between $425 million and $475 million, reflecting confidence in future financial performance.
- Product Sales Outlook: The company anticipates full-year sales for TRYNGOLZA and DAWNZERA to be between $100 million and $110 million and $110 million and $120 million, respectively, although a significant decline in second-quarter TRYNGOLZA revenue is expected due to the price reset effective April 1, with a gradual recovery anticipated post-June 30 approval.
See More
Ionis Pharmaceuticals Q1 Earnings Beat Expectations with 86.4% Revenue Growth
- Strong Earnings Report: Ionis Pharmaceuticals reported a Q1 GAAP EPS of -$0.56, beating expectations by $0.35, with revenue reaching $246 million, reflecting an impressive 86.4% year-over-year growth that boosts investor confidence.
- Cash Flow Status: As of March 31, 2026, Ionis had $1.9 billion in cash and short-term investments, a decrease of $633 million from year-end 2025, primarily due to the maturity of 0% convertible notes, indicating challenges in cash management.
- Sales Guidance Upgrade: The company raised its peak net sales guidance for olezarsen from over $2 billion to over $3 billion, driven by increased confidence in the sHTG market opportunity, signaling optimism for future growth.
- Improved 2026 Financial Guidance: Ionis revised its 2026 total revenue guidance from $800-825 million to $875-900 million, while reducing operating loss expectations from $500-550 million to $425-475 million, reflecting strong revenue performance and ongoing commercial success.
See More
Ionis (IONS) Q1 2026 Earnings Call Transcript
See More
Ionis Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Announcement: Ionis Pharmaceuticals is set to release its Q1 2023 earnings on April 29 before the market opens, with consensus EPS estimated at -$0.78 and revenue projected at $196.01 million, reflecting a 48.5% year-over-year increase.
- Earnings Estimate Adjustments: Over the last three months, EPS estimates have seen no upward revisions and three downward adjustments, while revenue estimates have experienced one upward revision and six downward changes, indicating market caution regarding Ionis's future performance.
- Product Review Progress: Ionis's zilganersen has received Priority Review for Alexander disease, which could support future revenue growth, although the overall market environment remains uncertain.
- Market Environment Impact: Amid disruptions in the Middle East, Ionis Pharmaceuticals and other healthcare stocks are viewed as oversold, potentially presenting buying opportunities for investors looking for value in the sector.
See More
GSK Receives FDA Priority Review for Hepatitis B Therapy
- FDA Priority Review: GSK announced that its hepatitis B therapy, bepirovirsen, has received priority review from the FDA, with a target action date of October 26, 2026, potentially offering a new treatment option for approximately 1.7 million patients in the U.S., significantly enhancing GSK's competitive position in the liver disease market.
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy designation for the New Drug Application, indicating its potential for significant clinical benefits in treating chronic hepatitis B, which further bolsters GSK's R&D reputation and market confidence.
- Successful Clinical Trials: The NDA is supported by data from the Phase 3 B-Well 1 and B-Well 2 trials, which met primary endpoints and demonstrated statistically significant and clinically meaningful functional cure rates, indicating GSK's innovative potential in chronic hepatitis B treatment.
- Global Regulatory Reviews: In addition to the U.S., bepirovirsen is undergoing regulatory reviews in Europe, Japan, and China, and if approved, it will further expand GSK's international market presence and strengthen its global business strategy.
See More
FDA Accepts Priority Review for Bepirovirsen by GSK and Ionis
- FDA Priority Review: The FDA has accepted GSK's New Drug Application for Bepirovirsen, developed in partnership with Ionis, for priority review, marking a significant advancement in chronic hepatitis B treatment, with a decision expected by October 26, 2026.
- Breakthrough Therapy Designation: Bepirovirsen has received Breakthrough Therapy designation from the FDA, indicating its potential in treating chronic hepatitis B, which may provide new treatment options for patients and enhance market competitiveness.
- Clinical Trial Support: The regulatory submission is supported by positive results from the global B-Well 1 and B-Well 2 trials, which demonstrated statistically significant functional cure rates, thereby bolstering its credibility for clinical use.
- International Regulatory Review: Bepirovirsen is also under review by the European Medicines Agency, the China National Medical Products Administration, and Japan's Ministry of Health, Labour and Welfare, highlighting its global market potential and broad impact on chronic hepatitis B patients.
See More
